ArticleCancer management and research2019

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.

Helei Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.